MedTrace Logo

Feasibility of ReSpace™ Hydrogel to Establish a Stable Cervical-rectal Space

NCT05369221 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-11-13

No results posted yet for this study

Summary

In this study, 5 subjects will be enrolled and the cumulative D2cc dose for rectum during brachytherapy will be recorded as the primary outcome measures.

Conditions

  • Uterine Cervical Neoplasms

Interventions

DEVICE

ReSpace™

All of the subjects will be injected with ReSpace™ hydrogel.

Sponsors & Collaborators

  • Shanghai Reunion Biotech Co.,Ltd.

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2023-10-10
Completion
2023-10-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369221 on ClinicalTrials.gov